Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH) - PubMed
4 hours ago
- #MASH
- #resmetirom
- #fibrosis
- Resmetirom is the first therapy to show MASH resolution and fibrosis improvement, gaining FDA approval in 2024 and EMA conditional approval in 2025.
- It is a liver-specific THR-β agonist that reduces intrahepatic fat and is generally well-tolerated.
- Recommended for non-cirrhotic fibrotic MASH patients, excluding those with cirrhosis, active liver disease, significant alcohol use, or untreated thyroid disorders.
- Treatment monitoring includes hepatic safety, thyroid function, and response assessment via non-invasive tests and ALT after 6-12 months.
- Real-world data shows rapid adoption of non-invasive eligibility assessments and early improvements in liver stiffness, often alongside GLP-1 receptor agonists.
- Semaglutide also approved for fibrotic MASH; optimal positioning of resmetirom and combination strategies with GLP-1 agonists are key priorities.
- Ongoing challenges include long-term impacts on liver-related and cardiometabolic outcomes.